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Simple Summary: We evaluated the effects of a commercial nutraceutical supplementation in
dogs naturally affected by Leishmania infantum. This nutraceutical supplement is proposed to
be added to dog diet to foster physiological immune-response during chronic leishmaniasis.
Parasite clearance is infrequently obtained by immune response in both the human and canine
leishmaniasis. Pharmacological therapies frequently fail in the elimination of L. infantum that could
have settled in deep organs, escaping immune responses and therapy. The conventional drug
therapy improves clinical signs, reduces parasitemia as well as relapse of infection. This nutraceutical
supplementation can improve the impaired immune response of the infected dogs to fight the disease.
Abstract: The use of nutraceuticals as immunomodulators in the treatment of visceral leishmaniasis
has generated interest in the current approaches to treat the disease. In this clinical and immunological
study, we investigated whether the administration of a nutritional supplement mediates the
immune-modulatory response in canine leishmaniosis (CL) and improves the clinical outcome
of the disease. With this purpose, we analysed T lymphocyte subsets in peripheral blood (PB) of
12 dogs naturally infected by Leishmania infantum, following treatment with a nutritional supplement.
The regulatory T (Treg) cells and the T helper (Th) 1 population were specifically evaluated. The animals
underwent complete clinical examination and blood sample collection for haematological, biochemical,
serological and immunological analysis before treatment (T0), one month (T30) and 3 months (T90)
after the onset of the nutraceutical supplementation. We observed that nutraceutical supplementation
was associated with immunomodulation of Th1 response and significant clinical improvement of the
animals. No side effects were observed. Therefore, a potential supportive role for the nutraceutical
supplement during canine leishmaniasis is proposed.
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1. Introduction
Canine Leishmaniasis (CL) is a relevant endemic zoonotic disease in Mediterranean region where
dogs are considered to be the main reservoirs hosts. In Europe, CL is caused by the protozoan
L. infantum and usually transmitted by phlebotomine sand flies, although non-vectorial transmission
is also reported [1–3]. Clinical symptomology and progression of CL is variable [4,5]. CL can range
from a self-limiting disease with sub-clinical appearance [6,7], to a non-self-limiting infection with
severe clinical features [4,8,9]. Subclinical or moderate infection is generally characterized by effective
anti-Leishmania Th1 response with interferon (IFN)-γ and tumour necrosis factor (TNF)-α production
that increases the leishmanicidal activity of the macrophages [10–12]. On the contrary, CL severe
disease is associated with poor cell-mediated immune response and the occurrence of a mixed Th1
and Th2 cytokine profile [13]. Involvement of CD4+CD25highFoxp3+ T regulatory cells (Treg) could
be of critical relevance during CL [14–16]. Treg regulate the recruitment and activation of immune
effectors [17]. During CL, Treg activity may suppress anti-parasite immune response and exacerbate
the L. infantum growth, favouring severe disease occurrence. On the contrary, Treg could avoid
both the immune-mediated tissue damage and autoimmune processes in CL [18–25]. In this regard,
we previously described the occurrence of CD8+CD3+ T and Th1 cell increase accompanied by Treg
decrease in CL [14].
Meglumine antimoniate, miltefosine and aminosidine are the only registered drugs for CL
in Europe [22]. Administration of Allopurinol during and after antimonial treatment avoids
relapses [22,26]. Therapy with Allopurinol alone should be continued for 6 months [27] or one
year [22,28,29]. The combination of miltefosine with Allopurinol and Amphotericin B represents
the second and the third lines of CL therapy [22]. Efficacy of CL therapies varies from poor to
good [22,30–32]. Majority of CL dogs clinically ameliorated after one month of CL therapy [33],
although a longer period is required to achieve complete clinical recovery. Reports of incremental
resistance to antimonial drugs in CL [34] has induced the discovery of new drugs or natural origin
compounds for the treatment of leishmaniasis in human and dogs [35]. Moreover, preventive
vaccination and topical ectoparasiticidals against sand-flies have been suggested [22].
Unbalanced diet and hyponutrition are associated with increased susceptibility to infection [36–39].
In addition, malnutrition was referred as a primary cause of immune suppression and could represent
a major risk factor for the susceptibility to leishmaniosis in humans and animals [40–43]. Since immune
cell homeostasis and metabolism are stringently correlated, this interdependence could open to
innovative immune-modulating therapeutic approaches for the treatment of infectious diseases [44,45].
In this context, the use of plant-derived nutraceuticals may regulate immune responses [46] and improve
the clinical outcome of infectious diseases in both human and dog models [47–50]. Cortese et al. [15]
reported that the combination of nutraceutical pet food with conventional therapy may modulate
immune responses in CL. Nutraceutical diet administration correlated with the Th1 response decrease
and Treg increase, and with the amelioration of CL clinical symptoms [15]. In addition, Segarra et al. [51]
reported the efficacy (marked improvement in clinical and clinicopathological signs) of a treatment
with dietary nucleotides and active hexose correlated compound in addition to N-methylglucamine
antimoniate in dogs with leishmaniasis. Sesquiterpene (-)-α-bisabolol has been described to be effective
in regulating Th1 response and in inducing clinical improvement in CL [52].
In the present study, we evaluated the efficacy of the administration of a commercial nutraceutical
supplementation in dogs naturally affected by CL. This supplement is a combination of: Krill oil and
flour, Cordyceps sinensis L., Gentiana Lutea L. and Eleutherococcus senticosus L., and is proposed to be
added to the normal diet of dogs to support the natural physiological immune-response against chronic
leishmaniasis. Cordyceps sinensis L. has been used as a tonic for longevity, endurance and vitality [53].
Such nutraceutical modulates immune responses [54,55], inhibits tumour cell proliferation [56],
enhances hepatic function [57], decreases plasma cholesterol levels [58] and exhibits hypotensive and
vasorelaxant properties [59]. Krill oil, extracted from the Antarctic krill (Euphausia superba), has been
described for its anti-oxidative effect, due to astaxanthin, which keeps intact the ω-3 polyunsaturated
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fatty acids (PUFA) and thereby protects them from oxidation [60]. Several studies suggest the health
benefits of PUFA, in particular eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), in terms
of cardiovascular and anti-inflammatory effects [61–63]. Gentiana lutea is an ancient medicinal plant
with its root (Gentianae radix) possessing the pro-drug. Phytochemically, it is characterized by the
presence of active constituents, like secoiridoids, iridoids and xanthones. Recently, it has been found
that this plant is a natural source of xanthone compounds that possess antioxidative, hypoglycemic,
anti-viral, anti-bacterial and hepatoprotective activities [64,65]. Eleutherococcus senticosus L. (Siberian
ginseng) is an “adaptogen”—a stabilizer of several physiological process to increase homeostasis and
stress resistance [66]. The synergy of various herbs allows to achieve a therapeutic activity [67].
In order to identify the potential immunomodulatory properties of the above nutraceutical
supplement, we analysed the immune profile of 12 L. infantum naturally infected dogs (Nutraceutical
Supplement group, NS-group), as compared with 20 sex/age-paired healthy dogs (Control group,
CTR-group) at diagnosis and during a three-month follow-up.
2. Materials and Methods
2.1. Ethical Statement
Dog owners provided formal consent to house the animals in adequate facilities, to treat their dogs
with the nutritional supplement and to take samples. Ethical Animal Care and Use Committee approval
was obtained (OPBA, CSV, University of Naples Federico II, prot. n. 2017/0069148). This research
avoided discomfort to the animals by following animal welfare guidelines.
2.2. Composition of the Nutraceutical
The commercial supplement is a combination of: Krill oil 3%, dry mushrooms (Cordyceps sinensis
L.) 2%, Krill flour 1%, Gentian (Gentiana Lutea L.) dry root and products obtained from the extraction
of herbs (Eleutherococcus senticosus L.).
2.3. Dog Enrolment and Study Design
Twelve domesticated CL-positive dogs were enrolled in Campania region (South Italy) under the
supervision of the veterinarians from the Department of Veterinary Medicine and Animal Productions
of the University of Study Federico II (Naples, Italy). Criterion followed for the inclusion of the subjects
in the study was (i) adult dogs in the homogenous age range of 5–7 years (to exclude age groups that
might have too immature or too compromised immune systems) with laboratory confirmed positivity
for leishmaniasis; (ii) clinical and pathological signs of CL; (iii) and indirect immunofluorescence
antibody test (IFAT) titre ≥ 160; iv) positivity of L. infantum DNA in sternal bone marrow (BM) aspirate,
assessed by nested polymerase chain reaction (n-PCR). The exclusion criteria followed was (i) pregnant
or lactating dogs (as reported by owners and in some cases, confirmation done through abdominal
ultrasonography); (ii) dogs suffering with hepatic or renal disease (haematological and biochemical
analysis); (iii) dogs suffering with concomitant infective diseases (see Section 2.7); and (iv) dogs treated
against leishmaniasis in the last 2 years (as reported by owners). In addition, 20 healthy dogs (12 males,
8 females, equivalent in age to sick dogs) were included as control subjects (CTR-group). Healthy dogs
were enrolled considering (i) clinical health condition (neither clinical signs of leishmaniasis or other
infectious diseases); (ii) no clinical–pathological abnormalities by routine laboratory tests; (iii) IFAT
negative (titre ≤ 1:40); (iv) negative n-PCR; and (v) exclusion of concomitant infectious diseases as
described below (see Section 2.7).
In the Nutraceutical Supplement group (NS-group), CL-positive dogs received no drug treatment
for 4 weeks before commencement of the trial and were administered the nutraceutical at the dose rate
of 0.5 g/kg body weight for 90 days, orally. Dogs were evaluated before treatment (T0), one month (T30)
and 3 months (T90) after the nutraceutical treatment. Accurate clinical examination and the blood
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sampling for haematological, biochemical, serological and immunological analysis were performed at
T0, T30 and T90.
The CTR-group was observed at T0 and provided both the normal control for the clinical
parameters and the normality range for immune cells in our trial to be compared with NS-group.
Leishmania DNA n-PCR detection was performed on sternal BM aspirates in enrolled dogs at T0.
Nutraceutical supplementation was regularly added to pet food by the same dog owners before
the diet administration. Diet satisfied the nutritional requirement of adult dogs in both CTR and NS
groups. All dogs were subjected to ecto- and endoparacitidal treatment before the commencement of
the study.
2.4. Clinical Evaluation of Dogs
Clinical assessment of leishmaniasis was done by veterinarians according to the criteria developed
by da Silva et al. [68]:
Systemic signs—Attitude: active (0), apathetic (1); fever: absence (0), presence (1); lameness:
absence (0), presence (1); nutritional status: normal (0), thin (1), cachectic (2); lymph nodes: normal (0),
enlarged (1); mucosal colour: normal (0), pale (1); bleeding: absence (0), presence (1).
Cutaneous signs—Bristles: good (0), regular (1), bad/opaque (2); ear/nasal hyperkeratosis: absence
(0), presence (1); nails: normal (0), long/onychogryphosis (1); skin lesion: absence (0), presence (1),
ulcer (2); muzzle depigmentation: absence (0), presence (1); alopecia: absence (0), presence (1).
Ocular signs—Blepharitis: absence (0), presence (1); keratoconjunctivitis: absence (0), serous (1),
mucopurulent (2).
All the individual scores were awarded to obtain a total sign-based score ranging between 0 and
19 (15 signs). Occurrence of other illnesses was monitored during the trial to rule out any positive dog.
The clinical scores (CS) were obtained prior to treatments (T0) and at 1 (T30) and 3 months (T90).
2.5. Blood Sample Collection
Ten millilitres of peripheral blood (PB) were collected by jugular venepuncture after 12 h of fasting.
Total PB amount was divided into three fractions. Complete blood count (CBC) was performed within
30 min from the collection using semi-automatic cell counter (Genius S, SEAC Radim Florence, Italy).
Thrombocytopenia or evidence of platelet clumping was evaluated by May–Grünwald–Giemsa-stained
blood smears. Blood chemistry analyses was performed on serum aliquots by automatic biochemical
analyser (AMS Autolab, Diamond Diagnostics, Holliston, MA, USA) using reagents from Spinreact
(Girona, Spain) to determine: blood urea nitrogen (BUN), creatinine, aspartate amino transferase (AST),
alanine-aminotransferase (ALT), gamma-glutamyltransferase (GGT), alkaline phosphatase (ALP), total
cholesterol, triglycerides, albumin and total serum proteins (TP). Serum protein electrophoresis was
also evaluated.
In addition, interferon-γ was assayed in serum using Elisa kits (Genorise, Philadelphia, PA, USA).
2.6. Serological and Molecular Assays
Presence of anti-Leishmania antibodies was detected by indirect immunofluorescence antibody test
(IFAT) using L. infantum promastigotes (WHO reference strain MHOM/TN/1980/IPT-1) as described [69].
The cut-off dilution was set at 1:160.
E. canis positivity was evaluated by IFAT using E. canis antigen in DH82 cells with a cut-off titre
of 1:80.
The sternal bone marrow aspirate for Leishmania and E. canis DNA detection by n-PCR was
performed as described [70,71].
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2.7. Diagnostic Procedure
Diagnosis of CL in all dogs with clinical or clinical–pathological signs attributable to the infection
was always confirmed by anti-Leishmania antibody titres (≥1:160) and positive molecular diagnosis.
IFAT was evaluated three times (T0, T30 and T90) in NS-group.
Negative IFAT (≤1:80) and PCR, combined with the absence of clinical signs on physical
examination, characterized the dogs to be included in the CTR group.
In CTR and NS-groups, dogs detected positive for Ehrlichia canis, Anaplasma phagocytophilum
morulae, Babesia canis trophozoites and microfilariae in peripheral blood smears were excluded from the
group. Ehrlichiosis was also evaluated as described above in Section 2.6. Dirofilaria immitis infection
was detected by Snap Canine Combo Heartworm Antigen Antibody Test (IDEXX).
2.8. Monoclonal Antibodies, Immunofluorescence, Flow Cytometry and Cell Culture
T cells and Treg cells were analysed by immune-fluorescence and flow cytometry (two-laser
equipped FACScalibur apparatus and the CellQuest analysis software, (Becton Dickinson, Franklin
Lakes, NJ, USA). Immune-fluorescence staining was performed by Fluorescin isothiocyanate (FITC),
Phycoerythrin (PE), Cy-chrome and Allophycocyanin (APC) labelled monoclonal antibodies (mAbs)
against dog CD3 (Clone CA17.2A12), CD4(Clone YKIX302.9), CD8 (Clone YCATE55.9), CD45 (clone
CA12.10C12), IFN-γ (Clone CC302), IL-4 (Clone CC303) and isotype-matched controls (Serotec
Ltd, London, UK). Intracellular Foxp3 was evaluated by a cross-reactive murine anti-FoxP3 mAb
(Clone FJK-16 s, eBioscience, San Diego, CA, USA) and commercial detection Kit (FoxP3 Staining
Set, eBioscience). Tregs were detected as per established protocols [14,15,72]. Peripheral blood
mononuclear cells (PBMC) were purified with density gradient, cultured in RPMI 1640 (Biochrom
GmbH Berlin, Germany), supplemented with 5% heat inactivated foetal bovine serum and 2 mM
glutamine (Biochrom) at 37 ◦C in 5% CO2/95% air and incubated overnight with Phorbol myristate
acetate (PMA) and Ionomycin (Sigma-Aldrich, St. Louis, MO, USA), in the presence of 5 µg/ml of
Brefeldin-A (Sigma-Aldrich, St. Louis, MO, USA), to analyse IFN-γ production [14,15,73,74]. IFN-γ
intracellular staining was obtained using a fixation/permeabilization kit (eBioscience). Forward Scatter
(FSC) and Side Scatter (SSC) parameter strategy was applied to all analysed samples [14,15].
2.9. Statistical Analysis
Blood count, blood biochemistry and inflammatory parameters were compared by General Linear
Model as:
yijk = µ + Gi + Tj + G × Tij + εijk
where: y is the dependent variable, µ is the mean, G is the group effect (i = NS, CTR), T is the time
effect (j = 0, 30, 60, 90), G × T is the first level of interaction and ε is the error effect.
When significant differences were found in the ANOVA, means were compared using Tukey’s test.
Clinical signs were analysed by non-parametric Wilcoxon signed-rank test. All the statistical
procedures were performed used JMP software version n. 9 (SAS Institute, Cary, NC, USA).
Immunological parameters were evaluated by Wilcoxon matched pairs test (Graph-Pad Prism Inc, San
Diego, CA, USA).
3. Results
3.1. Clinical and Laboratory Evaluation
All the enrolled sick dogs were symptomatic. A progressive improvement in the clinical response
was observed in NS-group during the 3 months of follow-up period. No mortality was observed in the
CTR and NS-group during the study. Clinical recovery was considered when a reduction in the clinical
score was observed during the study. Before treatment with the nutraceutical supplement (T0), the
mean clinical score in infected dogs was 6.0 (range 2–9), while the enrolled dogs showed an overall
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and progressive clinical improvement during follow-up (T30 mean score: 4.8, range: 1–8; T90 mean
score: 3.1, range: 1–6) (Table 1). Notably, IFAT titres showed a progressive reduction (Table 1).
Table 1. Evolution of clinical score (CS) and immunofluorescence antibody test (IFAT) titres
in dogs belonging to NS group at time 0 (T0) and after 1 (T30) and 3 months (T90) of
nutraceutical supplementation.
NS Group Dogs T0 T30 T90
1 CS 3 1 1
IFAT 1:1280 1:1280 1:320
2 CS 9 8 6
IFAT 1:640 1:640 1:80
3 CS 7 6 2
IFAT 1:640 1:640 1:320
4 CS 7 6 5
IFAT 1:1280 1:640 1:160
5 CS 6 6 4
IFAT 1:640 1:320 1:160
6 CS 7 6 4
IFAT 1:320 1:320 1:40
7 CS 5 5 3
IFAT 1:1280 1:640 1:1280
8 CS 9 6 2
IFAT 1:640 1:640 1:320
9 CS 7 3 3
IFAT 1:320 1:160 1:320
10 CS 6 3 3
IFAT 1:320 1:160 1:160
11 CS 5 2 2
IFAT 1:160 1:160 1:80
12 CS 3 3 2
IFAT 1:640 1:640 1:160
All haematological and biochemical parameters were within the normal range for adult dogs
and no signs of adverse effects were observed after clinical examination, demonstrating that
supplementation was well tolerated. Haematocrit (HT), mean corpuscular volume (MCV) and
mean corpuscular haemoglobin (MCH) decreased significantly (p < 0.01) while mean corpuscular
haemoglobin concentration (MCHC) increased significantly (p < 0.01) in NS-group after 90 days of
treatment. White blood cells (WBC) also decreased significantly (p < 0.05) at day 90. Aspartate amino
transferase (AST) and Blood Urea Nitrogen (BUN) resulted significantly (p < 0.01) higher at day 90
whereas Gamma Glutamyl Transferase (GGT) significantly increased at day 30 but decreased at day 90
compared to day 0. Beta2 and gamma globulins significantly decreased at both 30 and 90 days (p <
0.05 and p < 0.01, respectively). Interferon-γ decreased at both 30 and 90 days (p < 0.05) in NS-group
compared to CTR-group.
3.2. Immune Phenotype Analysis
We analysed by Flow Cytometry the CD8 T lymphocyte percentage in NS-Group. We observed a
moderate but significant decrease of CD8 T lymphocyte percentage between NS-Group and CTR-Group
at T0 (p = 0.02) and T30 (p = 0.01) (Figure 1). CD8 T lymphocyte percentage appeared to be slightly
recovered at T90 when compared to T0 and T30 and became similar to the level expressed in CTR dogs.
This occurrence suggests that nutraceutical supplementation was able to normalize CD8 T cell level in
NS-Group. In contrast, CD4 T lymphocyte percentage unchanged in NS-Group upon nutraceutical
supplementation (Figure 2B). Notably, the moderate decrease of CD8 T lymphocyte percentage and
the unchanged CD4 T lymphocyte percentage could explain why the CD4:CD8 T cell ratio remained
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substantially unmodified in NS-Group at T30 and T90 (Figure 2A). It is noteworthy that, although
the differences are not significant, the CD4–CD8 ratio appeared to be increased at T0 and T30 when
compared to the CTR-Group, while it seemed to be normalized at T90 and similar to the CD4–CD8
ratio expressed in the CTR-Group. Treg percentage in the NS-Group and CTR-Group revealed a
significant reduction at T0 (p = 0.01) and T30 (p = 0.01) (Figure 3A). Treg percentage restored only at
T90 in NS-Group dogs and became similar to CTR-Group (Figure 3A). This result strongly suggests
that Treg restoration could be correlated to the nutraceutical supplement administration.
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IFN-γ producing CD3 T Lymphocyte percentage at T0 as compared with CTR-Group. Nutraceutical
supplementation appeared to decrease IFN-γ production at T30 and T90 in NS-Group. Referred values
indicate results obtained in CTR-Group (dashed column), in NS-Group dogs at T0 (white column), T30
(grey column), and T90 (black column). Wilcoxon matched-pairs signed-rank test was used for the
statistical analysis. NS means not significant difference.
We evaluated whether nutraceutical supplement administration could modify the Th1 activity
in CL dogs. Th1 cell percentage increased in NS-Group at T0 compared with CTR-Group dogs (p
= 0.03) (Figure 3B). This result is in accordance with our previous study on L [14]. Nutraceutical
supplementation ad inistration appears to be associated with Th1 cell decrease at T30 (p < 0.0001)
and T90 (p = 0.01) in NS-Group. This evidence was also confir ed by ELISA approach in serum CL
dogs, since the IFN-γ detection changed from T0 (260.32 pg/mL) to T30 (196.25 pg/mL) and T90 (157.06
pg/mL) in NS-Group.
4. Discussion
Here, we des ribed a significant improvement in clinical conditions in CL dogs treated with a
nutraceuti al upplement. Moreover, IFAT titr s showed a progressive reduct on during the follow up
even if th use of antibody levels to assess clinical improvement is controversial [75–77].
No signs of adverse effects were observed after cli ical examination, showing that supplementation
was well tolerated. Notably, some significant differences n biochemical parameters were detected.
In particul r, AST was higher in NS-group th n in CTR after 30 (35.8 + 8.0 U/L) and 90 (46.8 + 6.6 U/L)
days of treatment vs. day 0 (37.1 + 8.2 U/L), but its levels were still comprised within physiological
range. Moreover, in case of l ver damage, increases in AS parallel those in ALT, which is c nsidered a
much more liver-specific marker [78], but ALT did not change after the supplement administration,
thus excluding even a liver overload.
Likewise, BUN was higher in the NS group than in CTR at days 30 (35.5 + 4.4 U/L) and 90
(40.0 + 10.1 U/L) compared to day 0 (29, 7 + 7.6 U/L), also in this case in the physiological range.
During eishmaniasis the kidney is primarily damaged [79]. Thus, the BUN dos ge can provide useful
informati n on the status of the kidneys. However, its prognostic value is clos ly lated to creatinin
levels [80], which w re not influenced in the NS group. Therefore, the detected increases of AST and
BUN have a limited diagnostic value in the NS-group dogs. In light of the clinical, biochemical and
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serological results, our study highlighted an improvement in the condition of CL dogs after 3 months
of treatment with oral nutraceutical supplementation (NS group).
Ingredients present in the nutraceutical supplement were described to exert anti-oxidative
and anti-inflammatory effects, cardiovascular benefits, hypoglycemic, anti-viral, anti-bacterial and
hepatoprotective responses. C. sinensis L. activates murine macrophages responsible of the production
of a variety of pro-inflammatory cytokines and IFN-γ synergizes with such nutraceutical in order
to amplify this response [81]. C. sinensis reduces the incidence of diabetes, which is due to an
increase in the portion of Treg cells/Th17 in the spleen and pancreatic lymph nodes [82]. Non-obese
diabetic (NOD) mice treated with C. sinensis extract showed slowed disease development. However,
in peripheral lymph nodes, treatment with C. sinensis extract increases the frequency of IFN-γ and Treg
cells producing Th1 cells. Moreover, Chen et al. [83] showed significantly reduced CD4+ T cells and
increased percentages of CD8+ T cells in peripheral blood mononuclear cells (PBMC) after C. sinensis
administration in mice affected by lupus-prone autoimmune.
Based on in vitro data, the anti-inflammatory activity arising from Gentiana lutea L. is represented
by the ability to inhibit myeloperoxidase enzymes, which are released during degranulation of
neutrophils and monocytes. Myeloperoxidase upregulation is known to contribute to the development
of inflammatory and immune-mediated complications [84].
Treg cells have been found to play a critical role to maintain self-tolerance and to prevent
autoimmune diseases. Moreover, after nutraceutical administration we observed a slight restoration of
Treg cells, whose low level has been associated with chronic CL [14,15]. Indeed, Treg levels appear
to be increased upon treatment and become similar to those of control dogs after 90 days (T90) of
nutraceutical administration. Notably, IFN-γ production progressively decreased in NS-group dogs.
Nutraceutical supplementation seems to specifically act on Treg and Th1 lymphocytes, since other
type of T cells appear to be unaffected or only moderately decreased. In this regard, the unaltered T
cell effector activity could ensure immune response against the parasite, while Treg increase and the
modulation of Th1 inflammatory response could preserve tissues from the immune-mediated damages
occurring in CL [15,18,19,21–25]. Moreover, the nutraceutical-induced immuno-modulation could also
improve the overall clinical conditions of sick dogs due to the reduction of the inflammatory context in
the pathophysiology associated with CL, such as immune-mediated thrombocytopenia [14]. Taken
in all, our results showed that this peculiar nutraceutical supplement could modulate Th1 immune
response and significantly improve clinical amelioration of the infected animals.
5. Conclusions
Nutraceuticals as a dietary supplement appear to be of tangible benefit in the clinical management
of dogs affected with chronic CL. In fact, the clinical improvement and a beneficial modulation of the
immune response are observed in this clinical trial. In particular, the reduction of potential adverse
inflammatory events, mediated by the exacerbated INF-γ secretion and Treg percentage decreasing
usually observed in CL [15,18,19,21–25], may be limited by the use of those nutraceuticals able to
reduce the pro-inflammatory cytokine production and to increase Treg percentage. Nutraceutical
supplementation appears that are able to improve the immune-modulatory response in the clinical
recovery of CL dogs, independently of the conventional anti-CL treatment. The present study does
not point to the replacement of CL with this nutraceutical supplementation, but suggests its use as an
adjunct therapy to the conventional medical treatment of chronic canine leishmaniasis. In this regard,
this study highlighted that nutraceutical supplement administration is associated with Th1 immune
response modulation and significant clinical improvement of the infected animals.
6. Limitations
This study has some limitations: (1) No evaluation was performed to establish which ingredient
is the most active in the complex of employed supplementation; (2) Absence of control group of dogs
treated with other anti-oxidant and other extracts of plants, different from those here employed; (3)
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Absence of control group of dogs treated with conventional anti-leishmanial therapy; (4) No blinded
study was conducted; (5) The trial has been performed only in 90 days-follow-up; (6) The limited
sample size (12 dogs).
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